Raymond E. Cabillot Sells 835 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 835 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $42.00, for a total transaction of $35,070.00. Following the transaction, the director now owns 334,646 shares in the company, valued at $14,055,132. The trade was a 0.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pro-Dex Price Performance

Shares of NASDAQ:PDEX opened at $40.66 on Friday. The stock’s 50 day moving average is $47.76 and its 200-day moving average is $33.72. Pro-Dex, Inc. has a twelve month low of $16.18 and a twelve month high of $59.60. The company has a quick ratio of 1.94, a current ratio of 3.41 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $132.51 million, a price-to-earnings ratio of 26.40 and a beta of 0.56.

Analyst Ratings Changes

Several research firms have weighed in on PDEX. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th. Ascendiant Capital Markets boosted their target price on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PDEX. Dimensional Fund Advisors LP increased its position in shares of Pro-Dex by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after acquiring an additional 3,067 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after purchasing an additional 900 shares during the last quarter. Bard Associates Inc. boosted its stake in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after purchasing an additional 2,031 shares during the last quarter. FMR LLC increased its holdings in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the last quarter. Institutional investors and hedge funds own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.